Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) EBITDA Margin (2017 - 2019)

Historic EBITDA Margin for Iterum Therapeutics (ITRM) over the last 3 years, with Q1 2019 value amounting to 55313.51%.

  • Iterum Therapeutics' EBITDA Margin fell 489245100.0% to 55313.51% in Q1 2019 from the same period last year, while for Dec 2019 it was 275732.43%, marking a year-over-year decrease of 2669225400.0%. This contributed to the annual value of 748.26% for FY2024, which is 4587200.0% down from last year.
  • Latest data reveals that Iterum Therapeutics reported EBITDA Margin of 55313.51% as of Q1 2019, which was down 489245100.0% from 10017.99% recorded in Q4 2018.
  • Iterum Therapeutics' 5-year EBITDA Margin high stood at 2637.25% for Q4 2017, and its period low was 55313.51% during Q1 2019.
  • In the last 3 years, Iterum Therapeutics' EBITDA Margin had a median value of 8338.38% in 2018 and averaged 13964.39%.
  • Per our database at Business Quant, Iterum Therapeutics' EBITDA Margin plummeted by -46194000bps in 2018 and then crashed by -489245100bps in 2019.
  • Over the past 3 years, Iterum Therapeutics' EBITDA Margin (Quarter) stood at 2637.25% in 2017, then plummeted by -280bps to 10017.99% in 2018, then plummeted by -452bps to 55313.51% in 2019.
  • Its EBITDA Margin was 55313.51% in Q1 2019, compared to 10017.99% in Q4 2018 and 9837.01% in Q3 2018.